The purpose of the Notice is to inform you about: (a) this Litigation, (b) the certification of the Class, (c) the terms of the Settlement, and (d) your rights in connection with a hearing held before the United States District Court, Northern District of California, Oakland Division on March 31, 2022, at 2:00 p.m., to consider the fairness, reasonableness, and adequacy of the Settlement and related matters. The judge presiding over this case is the Honorable Haywood S. Gilliam, Jr., United States District Judge. The Notice also describes the steps to be taken by those who wish to be excluded from the Class and, for those who remain Class Members, the steps necessary to seek to be potentially eligible to share in the distribution of the Net Settlement Fund in the event the Settlement is approved by the Court.

A class action is a type of lawsuit in which the claims of a number of individuals are resolved together, thus providing the class members with both consistency and efficiency. In a class action lawsuit, the Court selects one or more people, known as class representatives, to sue on behalf of all people with similar claims, commonly known as the class or the class members. In the Litigation, the Court has appointed Plaintiffs New York Hotel Trades Council & Hotel Association of New York City, Inc. Pension Fund and the Sheet Metal Workers’ Pension Plan of Southern California, Arizona & Nevada as the representatives of the Class and Lead Counsel as Class Counsel, for purposes of the Settlement.

The people who are suing are called plaintiffs, and those who are being sued are called defendants. In this case, the Defendants are Impax, George Frederick Wilkinson, Dr. Larry Hsu, Dr. Carole Ben-Maimon, and Bryan M. Reasons.

The Notice explains the lawsuit, the Settlement, your legal rights, what benefits are available, who is eligible for them, and how to get them. The purpose of the Notice is to inform you of this case, that it is a class action, how you might be affected, and how to exclude yourself from the Settlement if you wish to do so. It also is being sent to inform you of the terms of the approved Settlement, and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the approved Settlement, the approved Plan of Allocation, and the application by Lead Counsel for attorneys’ fees and litigation expenses.

The Notice does not express any opinion by the Court concerning the merits of any claim in the Litigation. Payments to Authorized Claimants will be made after any appeals are resolved, and after the completion of all claims processing. This process takes time.  Please be patient.

This Litigation arises under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and alleges that during the period between February 20, 2014 and August 9, 2016, inclusive, Defendants Impax, George Frederick Wilkinson, Dr. Larry Hsu, Dr. Carole Ben-Maimon, and Bryan M. Reasons made materially false and misleading statements about Impax’s business performance and conditions. More specifically, Plaintiffs allege that during the Class Period, Defendants misled investors regarding Impax’s collusion with pharmaceutical industry peers to fix generic drug prices and the impact of competition and price erosion on its sales of certain key products in its generics portfolio.

Plaintiffs allege that during the Class Period, Defendants knew or recklessly disregarded that Impax’s profits were inflated by collusive agreements with the Company’s peers to fix the prices of digoxin and pyridostigmine bromide. Plaintiffs further allege that, pursuant to the industrywide conspiracy’s “rules of the road,” Impax was required to, and did, cede market share to manufacturers as they entered the market in order to maintain supracompetitive pricing. As a result, Impax reported declines in gross margins attributed to, in large part, a decline in digoxin sales on May 11, 2015 after the market closed. Impax also announced that the Antitrust Division of the DOJ had issued a grand jury subpoena to Impax relating to price fixing of four generic drugs, including digoxin. Following the May 11 disclosures, Impax’s stock price declined 2.7% or $1.10 per share at closing on May 12, 2015. On August 10, 2015, Impax announced a reduction in gross margin guidance from mid-50% to low-50%, allegedly due to pressure on digoxin, causing Impax’s stock price to decline 3% or $2.07 per share. Plaintiffs allege that Defendants partially offset the diminishing returns on its digoxin scheme by giving investors false information about the true cause, extent, and impact of revenue declines on Impax’s generic drug portfolio, and in particular diclofenac sodium gel 3%, and falsely reaffirmed guidance relating to Impax’s generic drug portfolio that they knew they could not meet. On June 21, 2016, Impax updated its guidance and revealed it expected greater competition for generic products, particularly diclofenac, resulting in lower revenues and gross margins. That day, Impax common stock declined 11% or $3.53 per share, and its 2% Convertible Senior Notes declined $40 per $1,000 par value. On August 9, 2016, Impax announced quarterly results and provided updated guidance that reduced forecasted revenues by $49 to $89 million, with analysts attributing at least a substantial portion to diclofenac. Digoxin revenues also declined, contributing an estimated 15% to the revenue shortfall. Impax’s stock price declined 23% or $7.29 per share, and its 2% Convertible Senior Notes declined $78 per $1,000 par value.

On October 26, 2018, Lead Plaintiff filed its Second Amended Complaint for Violation of the Federal Securities Laws. On December 6, 2018, Defendants moved to dismiss this complaint, which was opposed by Lead Plaintiff. On August 12, 2019, the Court issued an order granting Defendants’ motion to dismiss. The United States Court of Appeals for the Ninth Circuit affirmed in part and reversed in part this decision on January 11, 2021.

In the course of the Litigation, the Settling Parties engaged the services of the Hon. Layn Phillips (Ret.), of Phillips ADR, a nationally recognized mediator. The Settling Parties engaged in a mediation session with Judge Phillips on September 17, 2020. While the Settling Parties did not reach an agreement to settle the Litigation at the mediation, the Settling Parties continued settlement negotiations with the assistance of Judge Phillips, who provided the Settling Parties with a Mediator’s Proposal on June 26, 2021. The Settling Parties each accepted the Mediator’s Proposal to settle the Litigation for $33 million.

If you are a member of the Class, you are subject to the Settlement unless you timely request to be excluded. The Class consists of all Persons that purchased or acquired Impax common stock or 2% Convertible Senior Notes between February 20, 2014 and August 9, 2016, inclusive. Excluded from the Class are: (i) Defendants; (ii) members of the immediate families of the Individual Defendants; (iii) Impax’s subsidiaries; (iv) the officers and directors of Impax during the Class Period; (v) any entity in which any Defendant has a controlling interest; and (vi) the legal representatives, heirs, successors and assigns of any such excluded person or entity. Also excluded from the Class will be any Person who timely and validly seeks exclusion from the Class. Anyone with questions as to whether or not they are excluded from the Class may call the Claims Administrator toll-free at 1-833-823-0051.

RECEIPT OF THE NOTICE DOES NOT NECESSARILY MEAN THAT YOU ARE A CLASS MEMBER OR THAT YOU ARE ENTITLED TO RECEIVE PROCEEDS FROM THE SETTLEMENT. IF YOU WISH TO BE POTENTIALLY ELIGIBLE TO RECEIVE A DISTRIBUTION OF THE SETTLEMENT PROCEEDS, YOU MUST COMPLETE, SIGN AND SUBMIT THE ENCLOSED CLAIM FORM POSTMARKED NO LATER THAN MARCH 21, 2022.

Plaintiffs and Lead Counsel believe that the claims asserted against Defendants have merit. Plaintiffs and Lead Counsel recognize, however, the expense and length of continued proceedings necessary to pursue their claims against Defendants through trial and appeals, as well as the difficulties in establishing liability, obtaining class certification and establishing damages. Plaintiffs and Lead Counsel have considered the amount of the Settlement, as well as the uncertain outcome and risk in complex lawsuits like this one. Such risks include, in particular, the risk that another motion to dismiss that Defendants filed after the Ninth Circuit’s decision would be granted and the risk, among others, that Plaintiffs would be unsuccessful in proving that Defendants’ alleged misstatements were materially false and misleading, made with scienter (that is, the requisite state of mind), or caused compensable damages to the Class.

In light of the amount of the Settlement and the immediacy of recovery to the Class, Plaintiffs and Lead Counsel believe that the approved Settlement is fair, reasonable and adequate, and in the best interests of the Class. Plaintiffs and Lead Counsel believe that the Settlement provides a substantial benefit now, namely $33 million in cash (less the various deductions described in the Notice), as compared to the risk that the claims would produce a smaller recovery, or no recovery after summary judgment, trial and appeals, possibly years in the future.

Defendants have denied and continue to deny each and all of the claims alleged by Plaintiffs in the Litigation. Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Litigation. Defendants also have denied and continue to deny, among other things, the allegations that Plaintiffs or the Class have suffered any damage, that Plaintiffs or the Class were harmed by the conduct alleged in the Litigation, or that the Litigation is properly certifiable as a class action for litigation purposes.

If there were no Settlement and Plaintiffs failed to establish any essential legal or factual element of the alleged claims, neither Plaintiffs nor the Class would recover anything from Defendants. If Plaintiffs were not to succeed in obtaining class certification, Defendants may have asserted the defense that the claims of Class Members were untimely under applicable statutes of limitations and statutes of repose. Also, if Defendants were successful in proving any of their defenses, the Class likely would recover substantially less than the amount provided in the Settlement, or nothing at all.

To be eligible for a payment from the Settlement, you must be a member of the Settlement Class and you must have timely completed and returned the Claim Form with adequate supporting documentation postmarked no later than March 21, 2022. The Claims Submission Deadline has now passed. 

Payments to Class Members will be determined by the Plan of Allocation on paragraphs 8-15 of the Notice.

As the Settlement is now approved, Final Judgment has been entered by the court on July 21, 2022. The Judgment will dismiss with prejudice the claims against Defendants and will provide that Plaintiffs, and all other Released Plaintiff Parties (as defined in ¶48 in the Notice) shall have waived, released, discharged, and dismissed each and every one of the Released Claims (as defined in ¶45 in the Notice), including Unknown Claims (as defined in ¶49 in the Notice), against each and every one of the Released Defendant Parties (as defined in ¶47 in the Notice) and shall forever be barred and enjoined from commencing, instituting, prosecuting, or maintaining any and all of the Released Claims against any and all of the Released Defendant Parties, whether or not they execute and deliver the Claim Form or share in the Settlement Fund. Claims to enforce the terms of the Settlement are not released.

“Released Claims” means any and all claims, rights, liabilities, and causes of action of every nature and description, including both known claims and Unknown Claims, whether contingent or absolute, mature or unmature, discoverable or undiscoverable, liquidated or unliquidated, accrued or unaccrued, including those that are concealed or hidden, regardless of legal or equitable theory, that Lead Plaintiff or any other member(s) of the Class asserted or could have asserted in any forum that both (i) arise out of, are based upon, or are related in any way to the allegations, transactions, facts, events, matters, occurrences, disclosures, statements, representations, or omissions referred to in the Action, and (ii) relate to the purchase or acquisition of Impax common stock or 2% Convertible Senior Notes by the Class during the Class Period. Notwithstanding the foregoing, “Released Claims” does not include claims relating to the enforcement of the Settlement.

“Released Defendants’ Claims” means all claims and causes of action of every nature and description, including both known claims and Unknown Claims (as defined in the Notice), whether arising under federal, state, common or foreign law, or any other law, that Defendants could have asserted against any of the Released Plaintiff Parties, including Lead Counsel, that arise out of or relate in any way to the institution, prosecution, or settlement of the claims in the Action, except for claims relating to the enforcement of the Settlement.

“Released Defendant Parties” means each and all of the Defendants, and each of their Related Persons.

“Released Plaintiff Parties” means the Plaintiffs, each and every Class Member, Plaintiffs’ Counsel, and each of their respective past or present trustees, officers, directors, partners, employees, contractors, auditors, principals, agents, attorneys, predecessors, successors, assigns, insurers, parents, subsidiaries, general or limited partners or partnerships, and limited liability companies; and the spouses, members of the immediate families, representatives, and heirs of any Released Plaintiff Party who is an individual, as well as any trust of which any Released Plaintiff Party is the settlor or which is for the benefit of any of their immediate family members. Released Plaintiff Parties does not include any Person who timely and validly seeks exclusion from the Class.

“Unknown Claims” means any and all Released Claims that Plaintiffs or any other Class Member do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Defendant Parties, and any and all Released Defendants’ Claims that any Defendant does not know or suspect to exist in his, her or its favor, which if known by him, her or it, might have affected his, her or its decision to enter into this Settlement, execute the Stipulation, and agree to all the various releases set forth herein, or might have affected his, her or its decision not to object to this Settlement or not exclude himself, herself or itself from the Class. Unknown Claims include, without limitation, those claims in which some or all of the facts composing the claim may be unsuspected, undisclosed, concealed, or hidden. With respect to any and all Released Claims and Released Defendants’ Claims, the Released Parties stipulate and agree that, upon the Effective Date, Plaintiffs and Class Members (as regards the Released Claims) and the Defendants (as regards the Released Defendants’ Claims) shall expressly waive and relinquish, and each Class Member shall be deemed to have and by operation of law and of the Judgment shall have, expressly waived and relinquished, to the fullest extent permitted by law, any and all provisions, rights and benefits conferred by California Civil Code §1542, or any law of any state or territory of the United States, or principle of common law or of international or foreign law, which is similar, comparable, or equivalent to Cal. Civ. Code §1542, which provides:

A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Judgment also will provide that Defendants and each of the other Released Defendant Parties shall be deemed to have waived, released, discharged, and dismissed as against the Released Plaintiff Parties all Released Defendants’ Claims which includes all claims and causes of action of every nature and description, including both known claims and Unknown Claims, whether arising under federal, state, common or foreign law, or any other law, that Defendants could have asserted against any of the Released Plaintiff Parties, including Lead Counsel, that arise out of or relate in any way to the institution, prosecution, or settlement of the claims in the Litigation, except for claims relating to the enforcement of the Settlement.

Lead Counsel has not received any payment for its services in pursuing claims against Defendants on behalf of the Class, nor has Lead Counsel been paid for its expenses. Before final approval of the Settlement, Lead Counsel intends to apply to the Court for an award of attorneys’ fees on behalf of all Plaintiffs’ Counsel from the Settlement Fund of no more than 30% of the Settlement Amount, plus interest. At the same time, Lead Counsel also intends to apply for the payment from the Settlement Fund for Plaintiffs’ Counsel’s litigation expenses in a total amount not to exceed $250,000, plus interest. The Court will determine the amount of the award of fees and expenses. Lead Counsel may apply for awards to the Plaintiffs in connection with their representation of the Class. Such sums as may be approved by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses.

If you fall within the definition of the Class as described in the Notice, and you are not excluded by the definition of the Class and you do not elect to exclude yourself from the Class, then you are a Class Member, and you will be bound by the approved Settlement, and by any judgment or determination of the Court affecting the Class. If you are a Class Member, you must submit a Claim Form and supporting documentation to establish your potential entitlement to share in the proceeds of the Settlement. A Claim Form can be downloaded from this website or you may request a Claim Form be mailed to you by calling toll-free 1-833-823-0051. You may also file a claim online on the File A Claim tab on this website. Those who exclude themselves from the Class, and those who do not submit timely and valid Claim Forms with adequate supporting documentation, will not be entitled to share in the proceeds of the Settlement unless otherwise ordered by the Court. Please retain all original records of your ownership of, or transactions in the shares, as they may be needed to document your claim.

As a Class Member, for purposes of the Settlement, you are represented by Plaintiffs, and Lead Counsel, unless you enter an appearance through counsel of your own choice at your own expense. You are not required to retain your own counsel, but if you choose to do so, such counsel must file a notice of appearance on your behalf.

If you do not wish to remain a Class Member, you may exclude yourself from the Class by following the instructions in the Notice. If you exclude yourself from the Class, you will not be eligible to receive any benefit from the Settlement and you should NOT submit a Claim Form but you will retain the right to be a part of any other lawsuit against any of the Released Defendant Parties (as defined in ¶47 in the Notice) with respect to any of the Released Claims (as defined in ¶45 in the Notice).

If you wish to object to the Settlement or any of its terms, the approved Plan of Allocation, or Lead Counsel’s application for attorneys’ fees and litigation expenses, and if you do not exclude yourself from the Class, you may present your objections by following the instructions in the Notice. If you exclude yourself from the Class, you are not entitled to submit an objection.

Each Class Member will be bound by all determinations and judgments in this lawsuit concerning the Settlement, whether favorable or unfavorable, unless such person or entity mails, by first-class mail (or its equivalent outside the U.S.), or otherwise delivers a written request for exclusion from the Class, addressed to Impax Securities Settlement, EXCLUSIONS, c/o JND Legal Administration, PO Box 91417, Seattle, WA 98111. The exclusion request must be received no later than March 4, 2022. Each request for exclusion must clearly indicate the name, address and telephone number of the person or entity seeking exclusion, that the sender requests to be excluded from the Class in Fleming v. Impax Laboratories Inc., et al., Case No. 4:16-cv-06557-HSG, and must be signed by such person. Such persons or entities requesting exclusion are also directed to provide the following information: the number of shares of Impax common stock or the 2% Convertible Senior Notes that the Person requesting exclusion (i) owned as of the opening of trading on February 20, 2014; and (ii) purchased, acquired and/or sold from February 20, 2014 through August 9, 2016, inclusive, as well as the number of shares, dates and prices for each such purchase, acquisition and sale. The request for exclusion shall not be effective unless it provides the required information and is made within the time stated above, or the exclusion is otherwise accepted by the Court. Should you elect to exclude yourself from the Class, you should understand that Defendants and the other Released Defendant Parties will have the right to assert any and all defenses they may have to any claims that you may seek to assert, including, without limitation, the defense that any such claims are untimely under applicable statutes of limitations and statutes of repose.

If you do not want to be part of the Class, you must follow these instructions for exclusion even if you have pending, or later file, another lawsuit, arbitration, or other proceeding relating to any Released Claim against any of the Released Defendant Parties. Excluding yourself from the Class is the only option that allows you to be part of any other current or future lawsuit against Defendants or any of the other Released Defendant Parties concerning the Released Claims. Please note, however, if you decide to exclude yourself from the Class, you may be time-barred from asserting the claims covered by the Litigation by a statute of repose.

If you ask to be excluded, do not submit a Claim Form because you cannot receive any payment from the Net Settlement Fund. If a person or entity requests to be excluded from the Class, that person or entity will not receive any benefit provided for in the Stipulation.

If the requests for exclusion from the Settlement exceed a certain amount, as set forth in a separate confidential supplemental agreement between Plaintiffs and Defendants (the “Supplemental Agreement”), Defendants shall have, in their discretion, the option to terminate the Settlement in accordance with the procedures set forth in the Supplemental Agreement.

The Settlement Hearing was held via Zoom on March 31, 2022, at 2:00 p.m. PT, before the Honorable Haywood S. Gilliam, Jr., of the United States District Court, Northern District of California, Oakland Division, Oakland Courthouse, Oakland, CA 94612. On July 15, 2022 the Court approved the Settlement, Plan of Allocation, and Lead Counsel’s motion for an award of attorneys’ fees and expenses. Final Judgment has been entered by the Court on July 21, 2022.

Any Class Member who does not request exclusion such that it is received no later than March 4, 2022, may object to the Settlement, the Plan of Allocation, or Lead Counsel’s request for an award of attorneys’ fees and litigation expenses. You can ask the Court to deny approval by filing an objection. You cannot ask the Court to order a different settlement; the Court can only approve or reject the settlement. If the Court denies approval, no settlement payments will be sent out and the lawsuit will continue. If that is what you want to happen, you must object.

Any objection to the court-approved Settlement must be in writing. If you file a timely written objection, you may, but are not required to, appear at the Settlement Hearing, either in person or through your own attorney. If you appear through your own attorney, you are responsible for hiring and paying that attorney. All written objections and supporting papers must (a) clearly identify the case name and number (Fleming v. Impax Laboratories Inc., et al., Case No. 4:16-cv-06557-HSG), (b) be submitted to the Court either by mailing them to the Class Action Clerk, United States District Court for the Northern District of California, Oakland Division, 1301 Clay Street, Suite 400 S, Oakland, CA 94612, or by filing them in person at any location of the United States District Court for the Northern District of California, and (c) be filed or postmarked on or before March 4, 2022.

The notice of objection must include documentation establishing the objecting Person’s membership in the Class, including the number of shares of Impax common stock or the 2% Convertible Senior Notes that the objecting Person (1) owned as of the opening of trading on February 20, 2014, and (2) purchased, acquired and/or sold during the Class Period, as well as the dates and prices for each such purchase, acquisition and sale, and contain a statement of reasons for the objection, copies of any papers, briefs, or other documents upon which the objection is based, a statement of whether the objector intends to appear at the Settlement Hearing, and the objector’s signature, even if represented by counsel. The objection must state whether it applies only to the objector, to a specific subset of the Class, or to the entire Class. In addition, the objector must identify all class action settlements to which the objector and his, her or its counsel has previously objected. Documentation establishing membership in the Class must consist of copies of brokerage confirmation slips or monthly brokerage account statements, or an authorized statement from the objector’s broker containing the transactional and holding information found in a broker confirmation slip or account statement. Objectors who desire to present evidence at the Settlement Hearing in support of their objection must include in their written objection or notice of appearance the identity of any witnesses they may call to testify and any exhibits they intend to introduce into evidence at the hearing.

You may not object to the Settlement or any aspect of it, if you exclude yourself from the Class.

You may file a written objection without having to appear at the Settlement Hearing. You may not appear at the Settlement Hearing to present your objection, however, unless you have first filed a written objection in accordance with the procedures described in the Notice, unless the Court orders otherwise.

You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. If you decide to hire an attorney, which will be at your own expense, however, he or she must file a notice of appearance with the Court so that the notice is received on or before March 4, 2022.

The Settlement Hearing may be adjourned by the Court without further written notice to the Class, other than a posting of the adjournment on the Settlement website, www.ImpaxSecuritiesSettlement.com. If you plan to attend the Settlement Hearing, you should confirm the date and time with Lead Counsel.

Unless the Court orders otherwise, any Class Member who does not object in the manner described in the Notice will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation, or Lead Counsel’s request for an award of attorneys’ fees and litigation expenses. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

Nominees who purchased or acquired Impax common stock or the 2% Convertible Senior Notes for beneficial owners who are Class Members are directed to: (a) request within seven (7) calendar days of receipt of the Notice additional copies of the Notice and the Claim Form from the Claims Administrator for such beneficial owners; or (b) send a list of the names and addresses of such beneficial owners to the Claims Administrator within seven (7) calendar days after receipt of the Notice. If a nominee elects to send the Notice to beneficial owners, such nominee is directed to mail the Notice within seven (7) calendar days of receipt of the additional copies of the Notice from the Claims Administrator, and upon such mailing, the nominee shall send a statement to the Claims Administrator confirming that the mailing was made as directed, and the nominee shall retain the list of names and addresses for use in connection with any possible future notice to the Class. Upon full compliance with these instructions, including the timely mailing of the Notice to beneficial owners, such nominees may seek reimbursement of their reasonable expenses actually incurred in complying with these instructions by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought and reflecting compliance with these instructions, including timely mailing of the Notice, if the nominee elected or elects to do so. Such properly documented expenses incurred by nominees in compliance with the terms of these instructions will be paid from the Settlement Fund. Copies of the Notice may also be obtained by calling toll-free 1-833-823-0051, and may be downloaded from the Important Documents page of this website.

The Notice contains only a summary of the terms of the approved Settlement. More detailed information about the matters involved in the Litigation is available on this website, including, among other documents, copies of the Stipulation and Proof of Claim Form. The Notice summarizes the approved Settlement. For the precise terms and conditions of the Settlement, please see the settlement agreement available on this website, or by contacting Lead Counsel below. You may also access the Court docket in this case, for a fee, through the Court’s Public Access to Court Electronic Records (PACER) system at https://ecf.cand.uscourts.gov, or by visiting the office of the Clerk of the Court for the United States District Court for the Northern District of California, Oakland Division, 1301 Clay Street, Suite 400 S, Oakland, CA 94612, between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays. All inquiries concerning the Notice and the Claim Form should be directed to:

DO NOT CALL OR WRITE THE COURT, THE OFFICE OF THE CLERK OF THE COURT, DEFENDANTS OR THEIR COUNSEL REGARDING THE NOTICE.